Modern Biopharmaceuticals: Design, Development and Optimization

Modern Biopharmaceuticals: Design, Development and Optimization

Editor(s): Jörg Knäblein

Published Online: 5 FEB 2008

Print ISBN: 9783527311842

Online ISBN: 9783527620982

DOI: 10.1002/9783527620982

About this Book

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.

With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.

Table of contents

    1. You have free access to this content
  1. Part Introduction: Introduction

  2. Part I: Biopharmaceuticals Used in Molecular Medicine - From Genome to Clinic — Correlation Between Genes, Diseases and Biopharmaceuticals

  3. Part I: Biopharmaceuticals Used in Molecular Medicine - siRNA — the Magic Bullet and Other Gene Therapeutical Approaches

    1. Chapter 6

      Adenovirus-based Gene Therapy: Therapeutic Angiogenesis with Adenovirus 5 Fibroblast Growth Factor-4 (Ad5FGF-4) in Patients with Chronic Myocardial Ischemia (pages 151–181)

      Michael McCaman, Francisco J. Castillo, Farah Fawaz, Yasushi Ogawa, Erik Whiteley, Elisabeth Lehmberg, Mei Tan, Jacob Kung, Bruce Mann, Erno Pungor and Gabor M. Rubanyi

  4. Part I: Biopharmaceuticals Used in Molecular Medicine - Mobilis in Mobile — Human Embryonic Stem Cells and Other Sources for Cell Therapy

  5. Part II: Biopharmaceuticals and Their Mode of Action - Quid pro Quo — Lysis vs. Coagulation in the Fine-tuned Balance of the Clotting Cascade

  6. Part II: Biopharmaceuticals and Their Mode of Action - Errare Humanum Est — What Causes Cancer and How to Selectively Fight Tumors

  7. Part II: Biopharmaceuticals and Their Mode of Action - Mundus Vult Decipi — High Mutation Rates of HIV and New Paradigms for Treatment

  8. Part III: Improving the Development of Biopharmaceuticals - Citius, Altius, Fortius — Acceleration by High Throughput and Ultra-HT

  9. Part III: Improving the Development of Biopharmaceuticals - In Vivo Veritas — Early Target Validation in Knock-out Mice and More

  10. Part III: Improving the Development of Biopharmaceuticals - Revolution by Evolution — Rational Design for Desire and Scientific Art of Optimization

  11. Part IV: Production of Biopharmaceuticals - The Industry's Workhorses — Mammalian Expression Systems

    1. Chapter 3

      PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins (pages 779–807)

      Chris Yallop, John Crowley, Johanne Cote, Kirsten Hegmans-Brouwer, Fija Lagerwerf, Rodney Gagne, Jose Coco Martin, Nico Oosterhuis, Dirk-Jan Opstelten and Abraham Bout

  12. Part IV: Production of Biopharmaceuticals - Vivat, Crescat, Floreat — A Ripe and Blooming Market for Transgenic Animals and Plants

    1. Chapter 6

      Production of Recombinant Proteins in Plants (pages 893–917)

      Victor Klimyuk, Sylvestre Marillonnet, Jörg Knäblein, Michael McCaman and Yuri Gleba

  13. Part IV: Production of Biopharmaceuticals - Alea Non Iacta Est — Improving Established Expression Systems

  14. Part IV: Production of Biopharmaceuticals - When Success Raises its Ugly Head — Outsourcing to Uncork the Capacity Bottleneck

  15. Part V: Biopharmaceuticals used for Diagnositics and Imaging - From Hunter to Craftsman - Engineering Antibodies with Nature's Universal Toolbox

  16. Part V: Biopharmaceuticals used for Diagnositics and Imaging - Find, Fight, and Follow-Target-specific Troika from Mother Nature's Pharmacopoiea

  17. Part V: Biopharmaceuticals used for Diagnositics and Imaging - Getting Insight—Sense the Urgency for Early Diagnostics

  18. Part VI: Advanced Application Routes for Biopharmaceuticals - Getting Inside - Quest for the Best and How to Improve Delivery

  19. Part VI: Advanced Application Routes for Biopharmaceuticals - Pathfinder — New Ways for Peptides, Proteins and Co

  20. Part VI: Advanced Application Routes for Biopharmaceuticals - Via Mala —the Stoney Road of DNA Delivery: Back-pack, Feed-back, and Pay-back

    1. Chapter 7

      Liposomal In vivo Gene Delivery (pages 1507–1519)

      Shigeru Kawakami, Fumiyoshi Yamashita and Mitsuru Hashida

  21. Part VI: Advanced Application Routes for Biopharmaceuticals - Getting Beyond — Rocket Science vs. Science Fiction

  22. Part VII: From Transcription to Prescription of Biopharmaceuticals - Dosis Facit Venenum — The Therapeutic Window between Systemic Toxicity and Lack of Efficacy

  23. Part VII: From Transcription to Prescription of Biopharmaceuticals - Happy End: Claim to Fame and Approval

    1. Chapter 4

      Considerations for Developing Biopharmaceuticals: FDA Perspective (pages 1637–1667)

      Kurt Brorson, Patrick G. Swann, Janice Brown, Barbara Wilcox and Marjorie A. Shapiro

  24. Part VIII: From Bench to Bedside — The Aftermaths - Think Big and Dealmaking for Growth — Global Changes in the Health-care Sector

  25. Part VIII: From Bench to Bedside — The Aftermaths - News and Views — Quo Vadis, Biopharmaceuticals?

  26. Part VIII: From Bench to Bedside — The Aftermaths - Light at the End of the Tunnel or Back to the Roots?

    1. You have free access to this content
    1. You have free access to this content
    1. You have free access to this content
    1. You have free access to this content

SEARCH